Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 7/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.39 |
| ▸ | ALPL | P05186 | 3/20 | 0.38 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3751097 | 0.91 | CYP11B2 (0.47) | CYP11B2CYP11B1XDHKCNH2SCN10A | |
| SCHEMBL747041 | 0.86 | CYP11B2 (0.45) | CYP11B2CYP11B1GRIA2KDM1A | |
| SCHEMBL3741359 | 0.85 | CYP11B2 (0.48) | CYP11B2CYP11B1GRIA2 | |
| SCHEMBL3741360 | 0.85 | CYP11B2 (0.48) | CYP11B2CYP11B1GRIA2 | |
| SCHEMBL3742615 | 0.85 | CYP11B2 (0.48) | CYP11B2CYP11B1GRIA2 | |
| SCHEMBL13048503 | 0.85 | CYP11B2 (0.53) | CYP11B2CYP11B1SCN10AGRIA2 | |
| SCHEMBL745723 | 0.85 | CYP11B2 (0.53) | CYP11B2SCN10AALPLCTPS1 | |
| SCHEMBL28410297 | 0.85 | CYP11B2 (0.55) | CYP11B2 | |
| SCHEMBL753993 | 0.85 | CYP11B2 (0.44) | CYP11B2CYP11B1KCNH2ALPL | |
| SCHEMBL3740351 | 0.85 | CYP11B2 (0.44) | CYP11B2CYP11B1KCNH2ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102803217-B | Aryl pyridines as aldosterone synthase inhibitors | NOVARTIS AG | 2015-06-17 | — | — | CN | claimed |
| EP-2429995-B1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | claimed |
| US-8383827-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | claimed |
| CN-102803217-A | Aryl pyridines as aldosterone synthase inhibitors | NOVARTIS AG | 2012-11-28 | — | — | CN | claimed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | claimed |
| CN-104892502-B | It is used as the aryl-pyridine of aldosterone synthase inhibitors | 诺华股份有限公司 | 2017-08-04 | — | — | CN | disclosed |
| CN-104892502-A | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG | 2015-09-09 | — | — | CN | disclosed |
| CN-102803217-B | Aryl pyridines as aldosterone synthase inhibitors | NOVARTIS AG | 2015-06-17 | — | — | CN | disclosed |
| US-8809545-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-8809545-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-8809545-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| EP-2429995-B1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8383827-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-8383827-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| CN-102803217-A | Aryl pyridines as aldosterone synthase inhibitors | NOVARTIS AG | 2012-11-28 | — | — | CN | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B2 4/4885CYP11B1 2/4885XDH 135/4885 |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B2 4/4885CYP11B1 2/4885XDH 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.